About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors

A Phase I/II, Open-Label, Safety, Pharmacokinetic and Efficacy Study of Ascending Doses of Oral CK-101 in Patients With Advanced Solid Tumors

NCT02926768•Checkpoint Therapeutics, Inc.

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Lung NeoplasmsCarcinoma, Non-Small-Cell LungLung Diseases+1 more

Interventions

CK-101

Locations

20

United States

Locations (20)

Research Site

Sarasota, Florida, United States

Research Site

St Louis, Missouri, United States

Research Site

Hackensack, New Jersey, United States

Research Site

Nashville, Tennessee, United States

Research Site

Greenslopes, Queensland, Australia

Research Site

Grafton, Auckland, New Zealand

Key Dates

Start Date

September 1, 2016

Primary Completion Date

September 1, 2020

Completion Date

June 1, 2022

Last Updated

July 26, 2022

Related Studies

RECRUITINGPhase 2

A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT06855771

Carcinoma, Non-Small-Cell Lung

RECRUITINGPhase 3

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

NCT06758401

Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell Lung+1 more

RECRUITINGPhase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

NCT06120140

Carcinoma, Non-Small-Cell Lung

NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

NCT05722340

Lung Diseases, Interstitial

Defining a Technique for the Use of Cryogenic Catheters for Biopsy and Ablation for the Diagnostic and Treatment of Pulmonary Lesions: An Ex-Vivo Human Lung Model Study.

NCT05948904

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798

Carcinoma, Non-Small-Cell Lung

View all related studies

Sponsors

Lead Sponsor

Checkpoint Therapeutics, Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 26, 2022Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions